NASDAQ:ETON - Eton Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 223.53 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.40
▲ +0.16 (4.94%)

This chart shows the closing price for ETON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eton Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETON

Analyst Price Target is $11.00
▲ +223.53% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eton Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 223.53% upside from the last price of $3.40.

This chart shows the closing price for ETON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Eton Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2022HC WainwrightLower Price TargetBuy$14.00 ➝ $11.00Low
10/14/2021B. RileyInitiated CoverageBuyHigh
9/7/2021HC WainwrightReiterated RatingBuy$14.00Low
8/16/2021B. RileyReiterated RatingBuyLow
8/9/2021HC WainwrightReiterated RatingBuy$14.00Low
6/29/2021HC WainwrightReiterated RatingBuy$14.00Low
6/1/2021B. RileyLower Price TargetBuy$13.00 ➝ $11.00Medium
3/17/2021HC WainwrightLower Price TargetBuy$15.00 ➝ $14.00Medium
1/4/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $15.00N/A
9/30/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $20.00High
8/24/2020HC WainwrightReiterated RatingBuy$18.00High
5/26/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $18.00High
5/15/2020B. RileyLower Price TargetBuy$12.00 ➝ $10.00Medium
3/30/2020HC WainwrightBoost Price TargetBuy$23.00 ➝ $26.00High
3/19/2020HC WainwrightReiterated RatingBuy$23.00Medium
1/28/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00High
12/30/2019HC WainwrightReiterated RatingBuy$21.00Medium
10/23/2019HC WainwrightReiterated RatingBuy$18.00 ➝ $21.00Low
9/20/2019B. RileyInitiated CoverageBuy$13.50High
8/5/2019Lake Street CapitalInitiated CoverageBuyLow
8/5/2019HC WainwrightReiterated RatingBuy$18.00High
6/21/2019HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Low
6/10/2019HC WainwrightInitiated CoverageBuy$15.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/27/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Eton Pharmaceuticals logo
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Today's Range

Now: $3.40
Low: $3.32
High: $3.44

50 Day Range

MA: $3.78
Low: $2.89
High: $4.45

52 Week Range

Now: $3.40
Low: $2.76
High: $8.66

Volume

1,194 shs

Average Volume

135,137 shs

Market Capitalization

$85.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Eton Pharmaceuticals?

The following sell-side analysts have issued reports on Eton Pharmaceuticals in the last twelve months: B. Riley, HC Wainwright, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ETON.

What is the current price target for Eton Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Eton Pharmaceuticals in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 239.5%.
View the latest price targets for ETON.

What is the current consensus analyst rating for Eton Pharmaceuticals?

Eton Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETON will outperform the market and that investors should add to their positions of Eton Pharmaceuticals.
View the latest ratings for ETON.

How do I contact Eton Pharmaceuticals' investor relations team?

Eton Pharmaceuticals' physical mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company's listed phone number is (847) 787-7361 and its investor relations email address is [email protected] The official website for Eton Pharmaceuticals is www.etonpharma.com. Learn More about contacing Eton Pharmaceuticals investor relations.